Statins are associated with reduced likelihood of sarcopenia in a sample of heart failure outpatients: a cross-sectional study

Valdiviesso, Rui; Sousa‐Santos, Ana Rita; Azevedo, Luís Filipe; Moreira, Emília; Amaral, Teresa; Silva-Cardoso, José; Borges, Nuno

doi:10.1186/s12872-022-02804-5

Cited by 16 publications

(18 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 However, other studies showed that statins effectively reduced some degree of muscle mass atrophy and prevented sarcopenia development. 17,18,38 In the present study, patients administered statins showed higher muscle mass at admission and discharge than those who were not. Nevertheless, the limited duration of the observational period, which spanned only a few months, might have precluded the identification of changes in skeletal muscle mass.…”

Section: Discussionsupporting

confidence: 50%

“…However, evidence regarding the effects of statins on muscle health in patients with sarcopenia is lacking. Evidence suggests that statin use is not associated with inferior muscle parameter values in patients with abdominal aortic aneurysms, 17 decreases the incidence of sarcopenia in patients with heart failure 18 and chronic kidney disease, 19 and, in part, has beneficial effects on muscle health. These studies did not consider the presence or absence of sarcopenia, and there are no reports on statin effects in patients with sarcopenia.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Statin use impairs muscle strength recovery in post‐stroke patients with sarcopenia

Matsumoto¹,

Yoshimura²,

Nagano³

et al. 2023

Geriatrics Gerontology Int

View full text Add to dashboard Cite

AimThe effects of statins on muscle health are not well established. Therefore, this study investigated the impact of statin use on muscle strength and mass recovery in patients with sarcopenia after stroke.MethodsThis retrospective cohort study included stroke patients with sarcopenia hospitalized between 2015 and 2021 at a post‐acute rehabilitation hospital. Sarcopenia was diagnosed using handgrip strength and skeletal muscle mass index measured using bioelectrical impedance analysis according to the 2019 criteria of the Asian Working Group for Sarcopenia. The study outcomes included handgrip strength and skeletal muscle mass index at hospital discharge. We used multivariate analyses to examine whether statin use was independently associated with the outcomes. Statistical significance was set at P < 0.05.ResultsOf the 586 patients enrolled, 241 (mean age 79.3 years, 44.4% men) presented with sarcopenia and were included in the analysis. Statin use was observed in 61 (25.3%) patients. Statin use was independently negatively associated with handgrip strength at discharge (β = −0.095, P = 0.032), but not with skeletal muscle mass index at discharge (β = 0.019, P = 0.692).ConclusionsStatin use was negatively associated with muscle strength recovery, but not with muscle mass in patients with sarcopenia who underwent rehabilitation after stroke. To maximize outcomes, sufficient consideration is needed for statin use in these patients. Geriatr Gerontol Int 2023; ••: ••–••.

show abstract

Section: Discussionsupporting

confidence: 50%

Section: Introductionmentioning

confidence: 99%

Statin use impairs muscle strength recovery in post‐stroke patients with sarcopenia

Matsumoto¹,

Yoshimura²,

Nagano³

et al. 2023

Geriatrics Gerontology Int

View full text Add to dashboard Cite

show abstract

“…A systematic review and meta-analysis showed that sarcopenia and heart failure often co-exist, and the prevalence estimates of sarcopenia vary between 10 and 69% in patients with heart failure [ 31 ]. Both sarcopenia and heart failure share common pathophysiological pathways involving muscle dysfunction, which include alterations in mitochondrial density and activity, fiber distribution, and oxidative stress [ 32 ]. However, previous studies haven't focused on particular type of heart failure [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

Sarcopenia index as a predictor of clinical outcomes among older adult patients with acute exacerbation of chronic obstructive pulmonary disease: a cross-sectional study

Zhao

et al. 2023

BMC Geriatr

View full text Add to dashboard Cite

Background Sarcopenia is a geriatric syndrome with progressive loss of skeletal muscle mass and function and has a negative impact on clinical outcomes associated with chronic obstructive pulmonary disease (COPD). Recently, the sarcopenia index (SI) was developed as a surrogate marker of sarcopenia based upon the serum creatinine to cystatin C ratio. We aimed to assess the value of SI for predicting clinically important outcomes among elderly patients with acute exacerbation of COPD (AECOPD). Methods This cross-sectional study included elderly patients with AECOPD in China from 2017 to 2021. Clinical data were collected from medical records, and serum creatinine and cystatin C were measured. Outcomes included respiratory failure, heart failure, severe pneumonia, invasive mechanical ventilation, and mortality. Binary logistic regression was used to analyze the association between SI and clinical outcomes. Results A total of 306 patients (260 men, 46 women, age range 60–88 years) were enrolled in this study. Among the total patients, the incidence of respiratory failure and severe pneumonia was negatively associated with SI values. After adjusting for potential confounding factors, binary logistic regression analyses showed that a higher SI was still independently associated with a lower risk of respiratory failure (odds ratio [OR]: 0.27, 95% confidence interval [CI]: 0.13–0.56, P < 0.05). In subgroup analysis, the incidence of respiratory failure was negatively associated with SI values in groups with both frequent exacerbation and non-frequent exacerbation. After adjustment for potential confounders, binary logistic regression analyses showed that a higher SI was also independently associated with a lower risk of respiratory failure in both groups (OR: 0.19, 95% CI: 0.06–0.64 and OR: 0.31, 95% CI: 0.11–0.85). However, there were no significant differences in the correlations between SI and the risk of heart failure, invasive mechanical ventilation, and mortality in all groups. Conclusion The SI based on serum creatinine and cystatin C can predict respiratory failure in patients with AECOPD and either frequent or infrequent exacerbations. This indicator provides a convenient tool for clinicians when managing patients with AECOPD in daily clinical practice.

show abstract

“… 15 ) Several studies have reported a lower rate of sarcopenia among participants using statins; however, scientific evidence is lacking. 16 )…”

Section: Sarcopenic Obesitymentioning

confidence: 99%

Prevalence of Sarcopenic Obesity in Various Comorbidities, Diagnostic Markers, and Therapeutic Approaches: A Review

Kumari

Khanna

2022

Ann Geriatr Med Res

View full text Add to dashboard Cite

The coexistence of sarcopenia and obesity characterizes sarcopenic obesity. In this condition, there is an imbalance between lean and fat mass amounts. It is a prevalent issue that is gaining prevalence among the elderly population. To evaluate the condition, allied health professionals may employ non-invasive diagnostic techniques, such as gait speed, skeletal muscle mass, and muscle strength. Nevertheless, early diagnosis and treatment of pathology are essential for preventing debilitating effects and providing the highest quality of care. This article reviews the prevalence of sarcopenic obesity in numerous medical conditions, such as cancer, arthritis, postoperative cases, diabetes mellitus, obesity, and metabolic syndrome. In addition, this paper aims to examine the available evidence regarding the prevalence of sarcopenic obesity in other conditions along with their diagnostic markers and therapeutic approaches.

show abstract

Statins are associated with reduced likelihood of sarcopenia in a sample of heart failure outpatients: a cross-sectional study

Cited by 16 publications

References 54 publications

Statin use impairs muscle strength recovery in post‐stroke patients with sarcopenia

Statin use impairs muscle strength recovery in post‐stroke patients with sarcopenia

Sarcopenia index as a predictor of clinical outcomes among older adult patients with acute exacerbation of chronic obstructive pulmonary disease: a cross-sectional study

Prevalence of Sarcopenic Obesity in Various Comorbidities, Diagnostic Markers, and Therapeutic Approaches: A Review

Contact Info

Product

Resources

About